Abstract 2438
Background
This study was carried out as descriptive and cross-sectional in order to determine the compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) levels of the nurses working in oncology-hematology and the factors affecting them.
Methods
The sample of the study consisted of 125 oncology-hematology nurses working in two private hospitals, one university hospital. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Descriptive statistics, numbers and percentages and X±SD were used according to the data type. The factors affecting dependent variables were tested with multilevel models (MLM).
Results
In the study, 89.6% (n: 112) of the nurses were women, 80% (n: 100) were unmarried, 70.4% (n: 88) have Bachelor’s degree, mean age was 26.82±5.32, and the average years of total working at oncology was 2.78±2.35, the average weekly working hours was 49.75 ± 4.26, 65.6% (n: 82) said that the social support is not enough. When the mean scores of the nurses were examined, the CF was 13.53±7.25, BO was 20.14±6.77, CS was 37.92±7.40, PS was 32.00±3.44, PR was 135.43±17.29. There was a statistically significant effect of weekly working hour on BO, CS and PS (p < 0.05). 1 hour more work per week leads to a 0.5 point decrease in CS mean scores, 0,45 points increase in BO mean scores and 0,18 points increase in PS mean scores. When we compare the nurses their answers to social support question, nurses who said that social support is insufficient, have 3.1 points higher CF, 2.6 points lower CS, and 8.8 points lower PR mean scores (p < 0.05).
Conclusions
In this study, it was found that nurses had moderate levels of CF, BO and CS. While having social support positively affected the dependent variables, it was found that the increase in the weekly working hours negatively affected. These results are a key finding for the managers of the institutions especially in providing the healthy working life of nurses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract